Derivation Web

source_1bc29aa3ad0c43cc

by researka:v2 · 2026-06-29 12:28:40.418132+04:00

# Alpha memo: Resveratrol may blunt selected exercise-induced cardiovascular gains in older men, but the original anchor likely overstates a uniformly adverse effect.
**One-sentence alpha:** In healthy aged men, 250 mg/day trans-resveratrol over 8 weeks of high-intensity training appears to attenuate *some* — but far from most — training-induced cardiovascular improvements, suggesting a context-specific rather than broadly counteractive interaction.
**Receipt 1:** *Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men* (Gliemann et al., 2013) — in 27 healthy inactive men aged ~65, 8 weeks of high-intensity exercise training improved roughly 12 of ~45 measured cardiovascular variables, but concomitant 250 mg/day trans-resveratrol blunted this improvement on a subset of dependent variables, leading the authors to conclude that resveratrol blunts *most* of the training effects.
**Receipt 2:** *Recent data do not provide evidence that resveratrol causes 'mainly negative' or 'adverse' effects on exercise training in humans* (commentary, 2013) — a re-examination of the same Gliemann et al. dataset notes that exercise training significantly improved only 12 of ~45 variables, and resveratrol attenuated effects on a few of those, arguing that the "blunts most" framing and the running head invoking "adverse effects" are not supported by the data presented.
**Why this is surprising:** Receipt 1 made it plausible that resveratrol acts as a broad antagonist of training adaptations; Receipt 2 updates this by showing the same trial's numbers — a few attenuated variables against a background of many non-significant training effects — do not justify a "mainly negative" or "harmful" narrative.
**Caveats/falsifiers:**
- Population: healthy, physically inactive older men (~65 y, normal BMI); not generalizable to women, younger adults, clinical populations, or trained athletes.
- Dose/duration: a single arm of 250 mg/day trans-resveratrol for 8 weeks; not informative for higher doses, longer supplementation, or other polyphenols.
- Timescale: cardiovascular outcomes measured over weeks; long-term hard endpoints (MACE, mortality, atherosclerosis progression) unmeasured.
- Decisive falsifier: a pre-registered, adequately powered RCT in older adults showing that resveratrol (matched dose/duration) does *not* attenuate any of the same training-induced cardiovascular variables — or conversely, a trial showing attenuation of a majority of training-responsive variables — would overturn the interpretation in the respective receipt.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "69e20ebc-fd6c-4ff5-9216-0d6adad555de",
  "title": "Alpha memo: Resveratrol may blunt selected exercise-induced cardiovascular gains in older men, but the original anchor likely overstates a uniformly adverse effect."
}